News and Events

Now available on demand.       Originally Presented Live: Monday, June 13th, 2022 10:00 AM This June, join the National CMV Foundation, Leading Physicians cCMV Testing Advocates, and Eurofins Viracor to learn more about congenital cytomegalovirus and how early testing with non-invasive sample types (like saliva) can lead to improved outcomes. This succinct and informat ...

Blood and urine-based cell-free DNA detection methods will provide healthcare practitioners with highly accurate, non-invasive tools to identify and monitor for infection, rejection, and severity of organ damage in transplant and COVID-19 patients. Eurofins Viracor, LLC, a leader in testing for infectious disease, immunology, and allergy, announced today that it has entered int ...

Why are we moving?Our relocation and expansion are consistent with our organizational goal of providing more comprehensive solutions for our clients. Building on a new site affords us the opportunity to create a purpose-built facility where we can maximize flexibility and efficiency of operations. Additionally, as our current and future testing demand continues to grow, we are ...

ASTS 2022 - New Dates!  8/4 - 8/7/2022 - Miami

OmniGraf™ – the first and only rejection assay on the market that combines the power of gene expression profiling (TruGraf^®) and donor-derived cell-free DNA (Viracor TRAC^®) in one non-invasive, easy-to-draw test. OmniGraf offers the highest positive predictive value (PPV) and negative predictive value (NPV) of any kidney test available, empowering clinicians and patients to make the best possible treatment decisions with the goal of improving long-term graft outcomes.

NEW YORK – While vaccines for SARS-CoV-2 have rolled out at home and abroad, there is still uncertainty about their long-term effectiveness against the virus, and questions linger about whether a booster shot will be necessary and how often individuals will need to get vaccinated to remain protected against the virus. Against this backdrop Eurofins Viracor has developed a test ...

As one of the first commercial labs to deliver COVID-19 testing, Eurofins Viracor, Inc. continues to invest in innovation with the launch of Coronavirus SARS-CoV-2 inSIGHT™ T Cell Immunity testing. Viracor’s inSIGHT™ T Cell Immunity test delivers a deeper understanding of a patient's response to viral antigens and gives healthcare providers critical insight to aid in treatment ...

Urine biomarker test will provide healthcare practitioners with a highly accurate, non-invasive tool to identify and monitor rejection and elevated risk of rejection in kidney transplant patients.